COVID-19 Disease and Coagulopathy: Assessment of Clotting Factor Levels in Patients With SARS-CoV-2 Infection
NCT ID: NCT04787510
Last Updated: 2021-09-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
50 participants
OBSERVATIONAL
2020-12-23
2021-06-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Analysis of the Coagulopathy Developed by COVID-19 Infected Patients
NCT04356950
Thrombosis and Covid-19
NCT04366778
Observational, Retrospective Study to Evaluate Coagulation Changes and the Influence of Antithrombin III Treatment in Patients With Severe COVID-19 Infection
NCT04651400
Safety and Efficacy of Therapeutic Anticoagulation on Clinical Outcomes in Hospitalized Patients With COVID-19
NCT04377997
Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)
NCT04372589
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Association between clotting factors levels and disease severity,morbidity and mortality in these patients.
Effect of anticoagulant therapy in the clotting factors' levels in these patients
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
low molecular weight Heparin as standard of care treatment
STANDARD OF CARE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* SINGED INFORMED CONSENT FORM
* POSITIVE PCR TEST FOR SARS-COV2 INFECTION
* FINDINGS IN CXR OR CT OF THE LUNGS CONSISTENT WITH INFECTION OF LOWER RESPIRATORY TRACT
Exclusion Criteria
* DENIAL TO PROVIDE INFORMED CONSENT FORM
* HISTORY OF MALIGNANCY
* PRIOR USE OF ANTICOAGULANT THERAPY
* PRIOR USE OF STEROIDS LONGER THAN 14 DAYS
* LACTATION-PREGNANCY
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
INTERNAL MEDICINE DEPARTMENT, 1ST WARD
UNKNOWN
University Hospital, Ioannina
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Liontos Angelos
CONSULTANT OF INTERNAL MEDICINE
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
HARALAMPOS MILIONIS, PROFESSOR
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Ioannina
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University General Hospital of Ioannina
Ioannina, Epirus, Greece
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
895/23-12-2020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.